32.40
32.40 (0%)
As of Feb 14, 2025
Beam Therapeutics Inc. [BEAM]
Source:
Company Overview
Beam Therapeutics Inc is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. Our vision is to provide life-long cures to patients suffering from serious diseases. To achieve this vision, we have assembled a platform that includes a suite of gene editing and delivery technologies as well as internal manufacturing capabilities.
| Country | United States |
| Headquarters | cambridge, massachusetts |
| Phone Number | 857-327-8775 |
| Industry | manufacturing |
| CEO | John Evans |
| Website | www.beamtx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $63.5 |
| Operating Profit | $-415.6 |
| Net Income | $-376.7 |
| Net Cash | $-154.5 |
Profit Ratios
| Gross Margin | $63.5 |
| Operating Margin | -654.3 |
| Profit as % of Revenues | -16.9% |
| Profit as % of Assets | -29.4% |
| Profit as % of Stockholder Equity | -51.4% |
Management Effectiveness
| Return on Equity | -51.4% |
| Return on Assets | -34.1% |
| Turnover Ratio | 5% |
| EBITA | $-415.6 |
Balance Sheet and Cash Flow Measures
| Total Assets | $1,103.8 |
| Total Liabilities | $370.3 |
| Operating Cash Flow | $-347.2 |
| Investing Cash Flow | $185 |
| Financing Cash Flow | $7.7 |
